INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BTIG Reiterates Buy Rating on INmune Bio Inc. (INMB)
January 28, 2025 10:26 AM ESTBTIG analyst Thomas Shrader reiterated a Buy rating and $21.00 price target on INmune Bio Inc. (NASDAQ: INMB)
The analyst comments "The promise of immune therapy in mCRPC remains high, and we see more NK involvement as the most obvious mechanism to add as T-Cell alone approaches (CPIs) have shown correlates of protection, but true clinical benefits remain fleeting. We also see the approach as a good match in prostate cancer as front-line anti-androgen-pathway drugs (Zytiga and Xtandi) are very powerful and tumors that escape these drugs are generally highly mutated and under... More
